ARTICLE | Company News
J&J gets option to AdoRx's adenosine receptor antagonists for lung cancer
March 8, 2019 5:30 PM UTC
AdoRx granted Johnson & Johnson an exclusive option to research, develop and commercialize adenosine receptor antagonists to treat lung cancer. AdoRx Therapeutics Ltd. (Edinburgh, U.K.) and Johnson &...